Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
84 hedge funds and large institutions have $29.5M invested in Carisma Therapeutics in 2022 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 31 reducing their positions, and 15 closing their positions.
0.1% less ownership
Funds ownership: 1.22% → 1.11% (-0.1%)
10% less funds holding
Funds holding: 93 → 84 (-9)
17% less call options, than puts
Call options by funds: $934K | Put options by funds: $1.12M
30% less capital invested
Capital invested by funds: $42.2M → $29.5M (-$12.6M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
48% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$478K |
| 2 |
Renaissance Technologies
New York
|
+$319K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$229K |
| 4 |
SWP
Stratos Wealth Partners
Beachwood,
Ohio
|
+$68.5K |
| 5 |
State Street
Boston,
Massachusetts
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
-$471K |
| 2 |
Two Sigma Investments
New York
|
-$407K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$402K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$322K |
| 5 |
Jane Street
New York
|
-$311K |
CARM Hedge Fund Activity: Q1 2022 in Review
84 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q1 2022, worth a combined $29.5M — down 30% from $42.2M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CARM and 8 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 16 added.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $478K. The largest seller was Prudential Financial, cutting an estimated $471K.
- 84 institutional investors held Carisma Therapeutics (CARM) as of Q1 2022, down from 93 in Q4 2021.
- Funds reported $29.5M of Carisma Therapeutics stock for Q1 2022, down 30% quarter-over-quarter.
- 8 funds opened new Carisma Therapeutics positions in Q1 2022 and 15 closed out, a net change of -7 holders.
- The largest Carisma Therapeutics buyer in Q1 2022 was Fidelity Investments, an estimated $478K added.
- The largest Carisma Therapeutics seller in Q1 2022 was Prudential Financial, an estimated $471K sold.
Based on aggregated 13F filings for Q1 2022.